Taysha Gene Therapies Inc (NASDAQ: TSHA) open the trading on Thursday, with great promise as it jumped 3.65% to $1.42, before settling in for the price of $1.37 at the close. Taking a more long-term approach, TSHA posted a 52-week range of $1.19-$4.32.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 129.39%. Meanwhile, its Annual Earning per share during the time was -137.69%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 61.69%. This publicly-traded company’s shares outstanding now amounts to $186.96 million, simultaneously with a float of $158.49 million. The organization now has a market capitalization sitting at $291.02 million. At the time of writing, stock’s 50-day Moving Average stood at $1.9918, while the 200-day Moving Average is $2.3854.
Taysha Gene Therapies Inc (TSHA) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Taysha Gene Therapies Inc’s current insider ownership accounts for 22.67%, in contrast to 73.63% institutional ownership. According to the most recent insider trade that took place on Jun 27 ’24, this organization’s 10% Owner bought 1,333,333 shares at the rate of 2.25, making the entire transaction reach 2,999,999 in total value, affecting insider ownership by 1,333,333. Preceding that transaction, on Nov 17 ’23, Company’s 10% Owner bought 100,000 for 1.63, making the whole transaction’s value amount to 163,000. This particular insider is now the holder of 16,566,667 in total.
Taysha Gene Therapies Inc (TSHA) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.09 per share during the current fiscal year.
Taysha Gene Therapies Inc’s EPS increase for this current 12-month fiscal period is 61.69% and is forecasted to reach -0.40 in the upcoming year.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Trading Performance Indicators
Let’s observe the current performance indicators for Taysha Gene Therapies Inc (TSHA). It’s Quick Ratio in the last reported quarter now stands at 5.20. The Stock has managed to achieve an average true range (ATR) of 0.12. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 22.61.
In the same vein, TSHA’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.87, a figure that is expected to reach -0.09 in the next quarter, and analysts are predicting that it will be -0.40 at the market close of one year from today.
Technical Analysis of Taysha Gene Therapies Inc (TSHA)
[Taysha Gene Therapies Inc, TSHA] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 18.88% While, its Average True Range was 0.1325.
Raw Stochastic average of Taysha Gene Therapies Inc (TSHA) in the period of the previous 100 days is set at 8.75%, which indicates a major fall in contrast to 26.14% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 84.10% that was lower than 87.33% volatility it exhibited in the past 100-days period.
